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ÖZET
Amaç:  Talyum  zehirlenmesi  genellikle  çinko  eksikliğini 
taklit eden tipik cilt lezyonları ile birliktedir. Bu çalışmanın 
amacı talyum zehirlenmesi bulunan hastaların tedavisinde 
oral çinko sülfatın rolünü değerlendirmektir.
Gereç ve yöntem: Bu klinik tedavi çalışması, Bağdat ve 
Basra Eğitim hastanelerinde Şubat 2008- Şubat 2010 ta-
rihleri arasında, talyum zehirlenmesi olan 37 hasta dahil 
edilerek gerçekleştirildi. 
Hastaların tümünden detaylı anamnez alındı ve tam bir 
klinik muayene gerçekleştirildi. Hastaların tümü, Talyum 
zehirlenmesi tanısı doğrulanıncaya kadar, 5 mg/kg günde 
üç kez oral çinko sülfat aldı. İdrarda Talyum kalorimetrik 
yöntemle ölçüldü ve hastaların tümünde pozitif bulundu. 
Talyum zehirlenmesi tanısı kesinleştirildikten sonra Talyum 
antidotu Prusya Mavisi 32 hastaya verildi.
Bulgular: Otuz yedi hastanın yaş ortalaması 24±5.3 yıl 
(5-33 yaş arası) idi. Ana dermatolojik bulgu saçlı deri ve 
ekstremiteleri tutan anagen saç kaybı idi. Ayrıca hastaların 
ayak sırtı ve bacaklarında ve yüzlerinde kirli kırmızı eki-
motik döküntü benzeri lezyonlar görüldü. Başlıca periferik 
nöropati olarak nörolojik belirtiler 21 (%55) hastada gö-
rüldü. İki hasta dışında hastaların tümü oral çinko sülfat 
tedavisine bir kaç gün içinde cevap verdi. Klin Deney Ar 
Derg 2011;2(2):133-7
Sonuç: Oral çinko sülfat talyum zehirlenmesinde özellikle 
deri ve saç bulguları için ve komplikasyonları ve ölüme gi-
dişi azaltmada etkili ve güvenli bir tedavi gibi gözüküyor.
Anahtar kelimeler: Talyum zehirlenmesi, oral çinko sülfat, 
tedavi, Irak
ABSTRACT
Objectives: Thallium poisoning is usually associated with 
typical dermatological features simulating that of zinc de-
ficiency. The aim of this study was to evaluate the role of 
oral zinc sulphate in the treatment of patients with thal-
lium poisoning.
Materials  and  methods:  This  clinical  therapeutic  trial 
study was conducted in Departments of Dermatology of 
Baghdad and Basrah Teaching Hospitals from February 
2008 - February 2010, where a total of 37 patients with 
thallium poisoning were enrolled. 
A detailed history was taken from all patients and com-
plete clinical examination was performed. All patients re-
ceived zinc sulphate in a dose of 5 mg/kg three times a 
day few days before confirming the diagnosis of thallium 
poisoning. Thallium in urine had been measured using the 
colorimetric method and was positive in all patients. After 
confirming the diagnosis of thallium poisoning, thallium 
antidotes Prussian blue was given to 32 patients.
Results: Age range of 37 patients was 5-33 (24±5.3) years. 
The dermatological findings were mainly: anagen hair loss 
affected the scalp and limbs. Also, dusky ecchymotic red 
dermatitis like rash was observed on the face and dor-
sum of hands and legs, while neurological manifestations 
were mainly of peripheral neuropathy, were reported in 21 
(55%) patients. All patients but two responded promptly 
to a trial of zinc sulphate within few days.
Conclusion: Oral Zinc sulphate appears to be an effective 
and safe treatment for thallium poisoning particularly for 
skin and hair features and in reducing its lethal progres-
sion and complications. J Clin Exp Invest 2011;2(2):133-7
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INTRODUCTION
Thallium is a heavy metal that has qualities of a per-
fect criminal poison. Its salts are tasteless, colorless 
and odorless, that dissolve completely in liquids, 
which are rapidly absorbed, and defy detection on 
routine toxicological screens. Thallium has been the 
agent of choice in several criminal poisonings.1-3
Elimination half-life of thallium is long, due to 
its large distribution volume. The estimated half-life 
in humans is reported between 1-3 days after low 
doses and between 1-1.7 days under clinical therapy 
after ingestion or exposure by a possible lethal dose. 
Other groups have reported an elimination half-life 
between 8-30 days. Minimum lethal dose (LD50) of 
thallium in humans is also highly variable. Average 
lethal dose for thallium sulfate has been reported to 
range from 10-15 mg/kg.4
Thallium poisonings are generally due to inges-
tion of the salts, but cases of inhalation of dusts or 
fumes from smelting, skin absorption and even from 
sniffing contaminated cocaine have been reported.5,6 
It is used in the manufacture of electronic compo-
nents, optical lenses, semiconductor materials, al-
loys, gamma radiation detection equipment, imita-
tion jewelry, artist’s paints, low temperature ther-
mometers, and green fireworks.5
In some parts of the world it is still used for 
killing rodents and this may lead to inadvertent in-
gestion by humans.7 Thallium poisoning is rare in 
Western societies. It has occasionally been the tool 
for murder.8 Emsley mentioned that a person in the 
UK poisoned eight people and two of them died.1 
An outbreak of thallium poisoning was reported in 
Baghdad in February 2008 where members of Iraqi 
Air  Force  Club  and  some  of  their  children  were 
poisoned by cake laced with thallium. Two of the 
children died,9 another two outbreaks of thallium 
poisoning were reported in Iraq at January 2009 to 
February 2010 where a total of thirty two patients 
that are evaluated.10
Its toxic effect is due to its ability to inhibit a 
number  of  intracellular  potassium-mediated  pro-
cesses and legends formations with protein sulfhy-
dril groups, inhibition of cellular respiration, inter-
action with riboflavin and riboflavin-based cofac-
tors, and distribution of calcium homeostasis.1,4
The diagnosis of thallium poisoning is not very 
easy and requires chemical analysis to confirm it. 
Demonstration of the presence of thallium in urine 
is the best diagnostic procedure available.4
Short-term  exposure  to  thallium  may  induce 
hair loss, skin lesions, and damage to the nervous 
system.4,11-14 The clinical features of short-term thal-
lium intoxication include gastrointestinal symptoms 
of nausea, vomiting, stomatitis, and diarrhea, fol-
lowed by severe painful dysesthesia and paraesthe-
sia in the distal limbs, erythematous rashes in the 
cheeks and perioral region, and hyperkeratosis with 
loss of hair in sub acute stage.2,3 In the long-term, 
complete hair loss and severe polyneuropathy have 
been noted. The severity of dermatological picture 
is supposed to be related to the severity of thallium 
intoxication.14
The  combination  of  rapid,  diffuse  alopecia, 
with neurological and gastrointestinal disturbance 
is  pathognomonic  for  thallium  toxicity.  The  hair 
mount, showing a tapered or bayonet anagen hair 
with black pigmentation at the base, which may be 
highly diagnostic before the onset of alopecia.12
Zinc sulphate had been used in the treatment 
of many skin diseases such as cutaneous leishma-
niasis15, recalcitrant viral warts16, Behcet’s disease17, 
rosacea18. Perifolliculitis capitis abscedens et suf-
fodiens19,  alopecia  areata  and  recurrent  aphthous 
stomatitis20, and it was proved to be safe and effec-
tive.
The present work was designed to report the 
role of oral zinc sulphate in the treatment of thal-
lium poisoning.
MATERIALS AND METHODS
This is a clinical therapeutic trial study that was 
carried out in the Departments of Dermatology of 
Baghdad and Basrah Teaching Hospitals from Feb-
ruary 2008 to February 2010, where a total of 37 
patients with thallium poisoning were included in 
the present work. Thirty two patients were seen at 
Basrah Teaching Hospital while the remaining 5 pa-
tients were examined at Bagdad Teaching Hospital.
A detailed history was done regarding the fol-
lowing points: age, sex, mode of intake, patient’s 
presenting complaints, time of onset and full der-
matological  examination  was  performed  looking 
for skin and hair manifestation and other systemic 
involvement concentrating on GIT and CNS organs. 
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capsule (MERK, France) in a dose of 5 mg/kg three 
times a day few days before confirming the diagnosis 
of thallium poisoning and before using any thallium 
antidotes (e.g. Prussian blue). Thallium in urine has 
been measured in the Poisoning Consultation Cen-
ter using the colorimetric method and was positive 
in all of patients. After confirming the diagnosis of 
thallium poisoning, 32 patients were examined in 
Basrah Teaching Hospitals received oral thallium 
antidotes (Prussian blue) (ABBOTT, France) in a 
dose of 1 g three time a day followed by 250 mg/
kg/day in divided qid as a maintains treatment until 
the 24–hour urine thallium return to normal range 
(0-5 mcg/day). While the remaining 5 patients that 
were seen in Baghdad Teaching Hospital did not 
take Prussian blue because the diagnosis of thallium 
poisoning was late.
Formal consent was taken from each patient or 
their parents prior to their inclusion in this work; in 
addition the approval of the ethical Committee of 
Scientific Council of Dermatology and Venereology 
of Iraqi Board for Medical Specializations was also 
obtained.
RESULTS
Thirty seven patients with thallium poisoning were 
evaluated. Including 26 males and 11 females (male/
female; 2.36/1), their ages ranged from 5-33 years 
with a mean age of 24±5.3 years.
All patients who ingested thallium accidently 
developed  immediate  onset  signs  and  symptoms 
of  thallium  intoxication  including  nausea,  vomit-
ing and diarrhea in 21 (55%) of them followed by 
mental and peripheral neurological complaints and 
within two weeks all patients of this group devel-
oped skin manifestations mainly severe hair loss in 
diffuse and patchy forms of anagen type, affecting 
mainly scalp and body hair.
Anagen hair loss was obvious for all the pa-
tients (Figure 1), it started in the second and third 
week,  as  diffuse  or  patchy  hair  loss  involving 
mainly the scalp and the lower limbs. The affected 
hair was either broken at the surface of the skin in 
black dots like pattern or diffusely lost, presenting 
as diffuse hair thinning or remarkable total alopecia. 
The remaining hairs at the affected area were eas-
ily plucked and they were in typical anagen phase. 
Microscopically the roots were pigmented having 
anagen features.
The skin rash appeared in all patients in the first 
week, it was dermatitis-like picture with ecchymot-
ic dusky red color that covered the face especially 
around the mouth and the limbs mainly on the dorsa 
of  both  hands  simulating  horse  shoe  appearance 
and that of acrodermatitis enteropathica or pellagra 
pictures (Figure 2). Acneiform rash of the face was 
seen in two patients.
The  neurological  findings  were  observed  in 
21(55%)  patients  as  peripheral  neuropathy  with 
marked  leg  and  foot  tenderness  and  paraesthesia 
which developed with in 2 to 4 days of thallium in-
toxication, muscular weakness was noted in most of 
those patients especially of the lower limbs and of 
variable severity.
Psychiatric findings were seen in 4 (10%) cases 
mainly in a form of personality changes, depression 
and apathy while others presented with anxiety and 
acute agitation.
All 37 patients were given 5 mg/kg (t.d.s) oral 
zinc sulphate as considered as a zinc deficiency be-
fore  the  definite  diagnosis  of  thallium  poisoning 
was established and before using oral Prussian blue. 
Surprisingly 35 out of 37 cases improved markedly 
within few days especially regarding the horse shoe 
like rash on the dorsa of their hands, alopecia and 
neuromuscular  involvement.  This  improvement 
started few days before given Prussian blue thalli-
um antidotes. Thirty two patients were examined in 
Basrah Teaching Hospital did receive oral thallium 
antidotes (Prussian blue), while the remaining 5 pa-
tients that were seen in Bagdad Teaching Hospital 
did not taken Prussian blue because the diagnosis of 
thallium poisoning was late.
Figure 1. Anagen hair lossSharquie KE, et al. Zinc sulphate in Thallium poisioning 136
J Clin Exp Invest   www.clinexpinvest.org   Vol 2, No 2, June 2011
Figure 2. Dermatits like lesions on dorsum of the hands
The patients were kept on this treatment for two 
weeks and no relapse was reported after complete 
clearance,  whereas  the  remaining  two  cases  who 
presented later with severe neurological symptoms 
and in spite of their dramatic response to the oral 
zinc sulphate regarding their dermatological symp-
toms, and after establishing the diagnosis of thallium 
poisoning they received adjuvant oral Prussian blue, 
but unfortunately died due to respiratory failure.
DISCUSSION
The  International  Program  on  Chemical  Safety 
(IPCS) of the World Health Organization (1996) has 
produced a detailed Environmental Health Criteria 
Monograph on thallium. The monograph concluded 
that in the general population, the total intake of 
thallium has been estimated to be less than 5 micro-
gram per day, mostly from foodstuffs, and that this 
does not constitute a threat to health.1
Many outbreaks of thallium poisoning occurred 
in Iraq as a result of criminal or accidental ingestion 
of thallium contaminated food during 2008-2010, 
the skin and neurological findings were the domi-
nant pictures.10,21
In  present  work,  thirty  seven  patients  were 
evaluated during the period between 2008 and 2010 
showed that the skin manifestations were very char-
acteristic of thallium poisoning, especially the se-
vere  anagen  alopecia  and  dermatitis  like  picture. 
These features had been similarly reported by other 
studies 21 and are so, characteristic that can lead into 
the right diagnosis. Other diagnoses that might be 
mistaken with thallium poisoning are acquired zinc 
deficiency, pellagra and erythema multiforme.15
All cases in this work improved dramatically 
within few days after treatment with oral zinc sul-
phate. The similarities of skin manifestations be-
tween thallium poisoning and that of pellagra and/or 
zinc deficiency, raise a question, does thallium poi-
soning interact in away or another with zinc, niacin 
or riboflavin base factor metabolism. Therefore, it 
causes their deficiency resulting in clinical features 
simulating that of these elements’ deficiency. These 
possibilities may explain why a zinc supplement is 
helpful for those patients with thallium poisoning. 
So these points should be considered in any further 
studies.
On the other hand, the dramatic response of 
patients with thallium poisoning to oral zinc sul-
phate therapy prior to the use of any specific thal-
lium antidotes and within a short period indicates 
that the response is attributed basically to the use of 
zinc sulphate, rather than to any other specific treat-
ments, particularly for hair and skin manifestations 
and possibly other clinical features.
Moreover,  the  dramatic  improvement  of  all 
cases after treatment with oral zinc sulphate neces-
sitates further studies to identifying the mechanism 
of its action including animal study that is strongly 
recommended.
The possible mechanism of action of zinc sul-
phate in the treatment of thallium poisoning may 
be through one or all of the following mechanisms. 
Zinc  may  also  impact  hair  and  skin  biology  via 
its  long-recognized,  potent  and  immunomodula-
tory  effects.22  Zinc  exerts  an  indirect  antioxidant 
action by induction of some substances that serve 
as  the  ultimate  antioxidant,  these  substances  are 
“metallothionein”.23  Zinc  is  an  essential  cofactor 
for over 300 enzymes [zinc metalloenzymes], many 
of  which  (e.g.  alkaline  phosphatase,  dopachrome 
tautomerase,  metallothionein  and  metalloproteas-
es) exert important functional activities in the hair 
follicle.24 Zinc is important for DNA stability and 
repair–parameters of evident importance in hair bi-
ology, since the epithelial hair matrix is one of the 
most rapidly proliferating and most damage-sensi-
tive tissues in the mammalian organism.25
Zinc may increase the renal elimination of thal-
lium and/or possibly interfere with its absorption 
from the gastro intestinal tract so ,that zinc act as 
chelating agent.1,4 Zinc is an essential cofactor for 
many body enzymes that it may counteract the ef-Sharquie KE, et al. Zinc sulphate in Thallium poisioning 137
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fect of thallium on the riboflavin and riboflavin co-
factors. So this may explain the dermatological and 
neurological improvement in patients with thallium 
poisoning after using oral zinc sulphate.24
In conclusion, oral zinc sulphate appears to be 
a safe and effective treatment for thallium poison-
ing especially in its early stages particularly before 
establishing the diagnosis and to be used as an adju-
vant therapy with thallium antidotes after establish-
ing the diagnosis of thallium poisoning in order to 
reduce or prevent its lethal progression and compli-
cations.
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